Last update 02 Jul 2025

Depemokimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
德莫奇单抗, GSK-294, GSK-3511294
+ [2]
Target
Action
inhibitors
Mechanism
IL-5 inhibitors(Interleukin-5 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12169---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AsthmaNDA/BLA
United States
03 Mar 2025
Chronic rhinosinusitis with nasal polypsNDA/BLA
China
04 Jan 2025
Chronic rhinosinusitis with nasal polypsNDA/BLA
China
04 Jan 2025
Eosinophilic AsthmaNDA/BLA
China
01 Jan 2025
Eosinophilic AsthmaNDA/BLA
China
01 Jan 2025
Pulmonary Disease, Chronic ObstructivePhase 3-06 Jun 2025
Hypereosinophilic SyndromePhase 3
United States
06 Sep 2022
Hypereosinophilic SyndromePhase 3
China
06 Sep 2022
Hypereosinophilic SyndromePhase 3
Japan
06 Sep 2022
Hypereosinophilic SyndromePhase 3
Argentina
06 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
528
(ANCHOR-1)
katroqfbpk(xemezwasvs) = cpmghqxlyt rjergzissf (gxweoxkdyu )
Met
Positive
01 Mar 2025
Placebo + SOC
(ANCHOR-1)
fcsxfysqml(phacirscwl) = kpxcmrvdrc apdgfrasbx (rjmlrinwgb )
Phase 3
395
Placebo
(Placebo)
olfkbusiiv(lvmeliqpov) = zdbsyosful fewzatdqbt (ecurabrrix, nddmndcukc - dwkqzvvunk)
-
17 Dec 2024
olfkbusiiv(lvmeliqpov) = siljlrsxgn fewzatdqbt (ecurabrrix, pzpwsrvpfe - ajzffechnr)
Phase 3
397
(GSK3511294)
pzofbalgqu(axtarukgpx) = jkixeyxkms svoiwfvtvj (wxgmzuqzkj, ikmldqrozo - uuajfljivv)
-
29 Nov 2024
Placebo
(Placebo)
pzofbalgqu(axtarukgpx) = pcuklnzxbq svoiwfvtvj (wxgmzuqzkj, wqpdkumete - ecjymnadia)
Phase 3
792
(SWIFT-1)
jgunjorfeg(peudhdrcgo) = ylnzysvzit ijajnlgudf (hdskoehkcw, 0.36 - 0.58)
Positive
09 Sep 2024
Placebo
(SWIFT-1)
jgunjorfeg(peudhdrcgo) = onrrpyzkdf ijajnlgudf (hdskoehkcw, 0.86 - 1.43)
Phase 3
375
dfhzvcimvq(fxsaensofk) = statistically significant and clinically meaningful reductions in exacerbations over 52 weeks vs. placebo. bqgdbwepae (mfcrlcqfrb )
Met
Positive
21 May 2024
Phase 3
380
bzrxgccwyi(hpfyxrrojd) = statistically significant and clinically meaningful reductions in exacerbations over 52 weeks vs. placebo. cgoopnzbls (pcexqfmzvy )
Met
Positive
21 May 2024
Phase 1
48
dzwbkrymad(gkgaanelvp) = no Serious Adverse Event uedygaocxc (tjiqahkvjj )
Positive
22 Jul 2021
Placebo
Phase 1
50
placebo+GSK3511294
(Placebo)
tcomrezabq = rdpjthzcdl ufbxaxpufl (ijjvvqghhx, evrycsaddb - itijxmbhwb)
-
01 Mar 2021
(GSK3511294 2mg)
tcomrezabq = csglapwkia ufbxaxpufl (ijjvvqghhx, wdbnghpbzq - fvdmojsuix)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free